Brief: Annexon Reports Phase 1 Results For Its Oral Small Molecule Inhibitor, Anx1502

Annexon

20/12/2023 22:56

Dec 20 (Reuters) - Annexon Inc  ANNX.O :
    * ANNEXON REPORTS PHASE 1 RESULTS FOR ANX1502, ITS ORAL
SMALL
MOLECULE INHIBITOR OF THE CLASSICAL COMPLEMENT PATHWAY
    * ANNEXON INC - ANX1502 GENERALLY WELL TOLERATED ACROSS
COHORTS
WITH NO SERIOUS ADVERSE EVENTS
    * ANNEXON INC- TABLET FORMULATION OF ANX1502 EXPECTED TO
ADVANCE
INTO PROOF-OF-CONCEPT STUDY IN PATIENTS WITH COLD AGGLUTININ
DISEASE (CAD) IN 2024

Source text for Eikon:  ID:nGNX8nPl8d 
Further company coverage:  ANNX.O 

 ((Reuters.Briefs@thomsonreuters.com;))